Imugene Seeks ASX Quotation for Additional Ordinary Shares

Imugene ( (AU:IMU) ) just unveiled an announcement.

Imugene Limited has applied to the ASX for quotation of a small number of additional ordinary fully paid shares, following the exercise or conversion of existing options or other convertible securities. The new securities, totaling 2,872 IMU shares issued on 4 and 5 March 2026, represent a routine capital markets adjustment with minimal impact on the company’s overall capital structure.

The move reflects standard administrative processes associated with employee or investor option exercises, rather than a new capital raising or strategic shift. For shareholders, the incremental dilution is negligible, and the listing maintains transparency and compliance with ASX requirements regarding changes in Imugene’s quoted securities.

The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.22 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.

More about Imugene

Imugene Limited is an Australian-listed biotechnology company focused on developing therapies in the healthcare sector. Its ordinary fully paid shares trade on the ASX under the ticker IMU, providing investors exposure to its activities in medical and life sciences innovation.

Average Trading Volume: 1,404,984

Technical Sentiment Signal: Sell

Current Market Cap: A$73.95M

For an in-depth examination of IMU stock, go to TipRanks’ Overview page.